This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsVoyager Acquisition(VACH.U)株式概要ボイジャー・アクイジション社は重要な事業を行っていない。 詳細VACH.U ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績1/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より84.1%で取引されている リスク分析マイナスの株主資本 株式の流動性は非常に低い 収益が 100 万ドル未満 ( $0 )3年未満の財務データが利用可能 すべてのリスクチェックを見るVACH.U Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW491,361 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA491,361 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$14.50該当なし内在価値ディスカウントEst. Revenue$PastFuture07m2016201920222025202620282031Revenue US$1.0Earnings US$0AdvancedSet Fair ValueView all narrativesVoyager Acquisition Corp. 競合他社Keen Vision AcquisitionSymbol: NasdaqGM:KVACMarket cap: US$70.5mIB AcquisitionSymbol: NasdaqCM:IBACMarket cap: US$54.0mHennessy AdvisorsSymbol: NasdaqGM:HNNAMarket cap: US$77.8mStarry Sea AcquisitionSymbol: NasdaqCM:SSEAMarket cap: US$78.6m価格と性能株価の高値、安値、推移の概要Voyager Acquisition過去の株価現在の株価US$14.5052週高値US$20.1052週安値US$10.08ベータ01ヶ月の変化13.28%3ヶ月変化0.62%1年変化38.76%3年間の変化n/a5年間の変化n/aIPOからの変化45.00%最新ニュースお知らせ • May 16Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.お知らせ • Sep 24Voyager Acquisition Corp. announced delayed 10-Q filingOn 09/23/2024, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • May 16Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.お知らせ • Sep 24Voyager Acquisition Corp. announced delayed 10-Q filingOn 09/23/2024, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.株主還元VACH.UUS Capital MarketsUS 市場7D4.3%0.8%-1.5%1Y38.8%1.1%16.0%株主還元を見る業界別リターン: VACH.U過去 1 年間で1.1 % の収益を上げたUS Capital Markets業界を上回りました。リターン対市場: VACH.U過去 1 年間で16 % の収益を上げたUS市場を上回りました。価格変動Is VACH.U's price volatile compared to industry and market?VACH.U volatilityVACH.U Average Weekly Movementn/aCapital Markets Industry Average Movement3.7%Market Average Movement7.2%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.2%安定した株価: VACH.Uの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のVACH.Uのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO(最高経営責任者ウェブサイト2023n/aAdeel Rouf Enniswww.voyageracq.comVoyager Acquisition Corp.は重要な事業を行っていない。ボイジャー・アクイジション・コーポレーションは、1つまたは複数の企業または団体との合併、株式交換、資産買収、株式購入、組織再編、または類似の企業結合を行うことに重点を置いている。ヘルスケアまたはヘルスケア関連分野のビジネスに焦点を当てる予定である。ボイジャー・アクイジション・コーポレーションは2023年に設立され、ニューヨーク州ブルックリンに本社を置いている。もっと見るVoyager Acquisition Corp. 基礎のまとめVoyager Acquisition の収益と売上を時価総額と比較するとどうか。VACH.U 基礎統計学時価総額US$109.67m収益(TTM)US$6.74m売上高(TTM)n/a16.3xPER(株価収益率0.0xP/SレシオVACH.U は割高か?公正価値と評価分析を参照収益と収入最新の決算報告書(TTM)に基づく主な収益性統計VACH.U 損益計算書(TTM)収益US$0売上原価US$0売上総利益US$0その他の費用-US$6.74m収益US$6.74m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益(EPS)1.05グロス・マージン0.00%純利益率0.00%有利子負債/自己資本比率0%VACH.U の長期的なパフォーマンスは?過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/06/11 15:13終値2026/06/09 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Voyager Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.
お知らせ • Sep 24Voyager Acquisition Corp. announced delayed 10-Q filingOn 09/23/2024, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Voyager Acquisition Corp. announced delayed 10-Q filingOn 05/15/2026, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 25Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction.Veraxa Biotech AG entered into a definitive business combination agreement to acquire Voyager Acquisition Corp. (NasdaqGM:VACH) from Voyager Acquisition Sponsor Holdco LLC and others for approximately $1.4 billion in a reverse merger transaction on April 22, 2025. Under the terms of the Business Combination Agreement, VERAXA’s equity value contribution into the Business Combination will amount to approximately $1.3 billion. Accordingly, VERAXA’s shareholders will receive approximately 130 million ordinary shares of the combined company in exchange for their existing VERAXA shares. Existing VERAXA shareholders and management will not receive any cash proceeds as part of the transaction and will roll over 100% of their equity into the combined company. In accordance with the terms and subject to the conditions of the Business Combination Agreement, (i) each issued and outstanding ordinary share in the Company will be cancelled and exchanged for the fraction of a PubCo Class A ordinary share equal to the Exchange Ratio (as defined in the Business Combination Agreement); (ii) (x) each issued and outstanding SPAC Unit will be automatically detached and the holder will be deemed to hold one SPAC Class A ordinary share and one-half of a SPAC warrant and (y) each issued and outstanding SPAC Class A ordinary share and SPAC Class B ordinary share will be cancelled and exchanged for one PubCo Class A ordinary share; and (iii) each issued and outstanding whole SPAC warrant will be converted into a whole warrant to purchase one PubCo Class A ordinary share. In addition to the consideration described above, the Company Shareholders shall have the right to receive an aggregate of up to 5,000,000 PubCo Class A Ordinary Shares (the “Earnout Shares”) during each of the three fiscal years after the Closing Date in accordance with Section 2.8 of the Business Combination Agreement and applicable Swiss Law. Post acquiistion completion, VERAXA Biotech shareholders will own 79.2% stake, SPAC shareholders will own 15.4%, sponsor shares will be 3.9% and PIPE shareholders will own 1.5%. In the event that the Business Combination Agreement is terminated by SPAC pursuant to Section 10.1(g) or Section 10.1(i) of the Business Combination Agreement, the Company shall pay to SPAC a termination fee of $12,500,000 within five (5) Business Days following such termination; provided, that to the extent the Business Combination Agreement is terminated and (i) it is concurrently or subsequently discovered by SPAC or that the Company breached Section 6.3 of the Business Combination Agreement prior to any such termination or enters into any written agreement to participate in an alternative transaction, then in addition any termination fee payment owing to SPAC, the Company shall pay to SPAC the greater of (A) $12,500,000 and (B) 1% of the enterprise value of such alternate transaction. The boards of directors of both Voyager and VERAXA have unanimously approved the Business Combination. The transaction is subject to approval of Voyager’s and VERAXA’s shareholders and the satisfaction of certain other customary closing conditions, including but not limited to, (i) the Registration Statement has become effective, PubCo’s listing application with Nasdaq is approved and, the PubCo Class A ordinary shares to be issued in connection with the Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance, the absence of a legal prohibition on consummating the transaction, compliance by Sponsor with certain provisions in the Sponsor Support Agreement, compliance by the Company Shareholders with certain provisions in the Shareholder Support Agreement and the delivery of customary certificates and ancillary agreements. Voyager and VERAXA expect the Business Combination to close in the fourth quarter of 2025. Anne Martina Group acted as financial advisor and Andrew Tucker of Duane Morris LLP acted as legal advisor for Veraxa Biotech AG. Michael J. Blankenship of Winston & Strawn LLP acted as legal advisor for Voyager Acquisition Corp. Claudio Bazzi of Bratschi AG acted as legal advisor to Voyager Acquisition.
お知らせ • Sep 24Voyager Acquisition Corp. announced delayed 10-Q filingOn 09/23/2024, Voyager Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.